Diana Florescu
Infectious Disease · Omaha, NENPI 1063464980
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,053 of the $11,190 with a category attached, or 89.8%. Merck accounts for 83.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $5,246 and has fallen 80.9% since, to $1,000 in 2022.
Across 16 payments — averaging $699.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$9K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Astellas Pharma US Inc$40
- Insmed, Inc.$16
Across 416 payments — averaging $6650.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1M
- Bavarian Nordic A/s$800K
- Astellas Pharma Global Development$259K
- Regeneron$254K
- Takeda Pharmaceuticals U.S.A., Inc.$172K
- Shire North American Group Inc$114K
- plus $124K from 2 others
What the payments were for
- Consulting fees$10,05390%
- Travel & lodging$8377%
- Food & beverage$2442%
- Education$561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $9,394 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,740 |
| Astellas Pharma US Inc | 1 | $40 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVYMIS$3,063
How this compares
$11,190 in reported general payments places this provider in the 80th percentile of 55 infectious disease providers in Nebraska.
Other infectious disease in Omaha
- Rudolf KotulaOmaha$221K
- Marvin BittnerOmaha$100K
- Mark RuppOmaha$76K
- Trevor VanschooneveldOmaha$56K
- Nada FadulOmaha$26K
- Alison FreifeldOmaha$15K
- Amir GholamiOmaha$12K
- Andre KalilOmaha$11K
- Kelly CawcuttOmaha$11K
- Jeffrey SartinOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.